Research programme: sodium channel antagonists - Zenyth Therapeutics
Alternative Names: AM 66Latest Information Update: 13 Jul 2007
At a glance
- Originator Zenyth Therapeutics
- Class
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pain
Most Recent Events
- 01 Dec 2005 Amrad Corporation is now called Zenyth Therapeutics
- 21 Aug 2003 Preclinical trials in Pain in Australia (unspecified route)